Monthly Archives:

Progression Uncommon during Treatment with RA-223

San Francisco—Radium-223 (Ra-223), an alpha emitter that selectively targets bone metastases, has been shown to improve survival in patients with castration-resistant prostate cancer and bone metastasis and is standard treatment for those patients. However, according to researchers, the imaging response during Ra-223 therapy is not well defined. Daniel Keizman,  MD, and colleagues recently conducted a study designed to describe the ... Read More »

Responses in African American Men Treated with Abiraterone Acetate

San Francisco—Previous studies have documented a disparity between African Americans and other racial groups in incidence and mortality in prostate cancer. Abiraterone acetate was shown to improve overall survival and was approved by the US FDA for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). However, according to Michael D. Stolten, MD, and colleagues, phase III trials of ... Read More »

Survival Benefit of Abiraterone Acetate with Longer ADT Duration

San Francisco—Results of a retrospective review of clinical data of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with 1000 mg abiraterone acetate daily plus 5 mg prednisone twice daily were reported during a poster session at the Genitourinary Cancers Symposium. The poster was titled Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer after Chemotherapy: A Real Life Retrospective Analysis of ... Read More »

Renal Function Not Impaired with Androgen Deprivation Therapy

San Francisco—There are known adverse effects associated with androgen deprivation therapy (ADT) in patients with prostate cancer; however, according to researchers there are few data on whether ADT affects renal function. Koji Mitsuzuka, MD, PhD, and colleagues conducted a study designed to assess changes in renal function in response to ADT for 1 year. Results of the study were presented ... Read More »